AstraZeneca licenses skin disease drugs to LEO Pharma
1 July 2016 | By Victoria White, Digital Content Producer
AstraZeneca has entered into an agreement with LEO Pharma for the global licence to tralokinumab in skin diseases.
List view / Grid view
News
BMS and PsiOxus to evaluate Opdivo and enadenotucirev in cancer
1 July 2016 | By Victoria White, Digital Content Producer
The companies are to evaluate the safety, tolerability and efficacy of enadenotucirev and Opdivo in a range of tumour types in late-stage cancer patients...
CPhI China Report launched at CPhI China 2016
30 June 2016 | By CPhI
The report was released at CPhI China 2016 and unequivocally shows the confidence of international companies in the expanding Chinese market...
Global urological cancers market to double by 2022, says GBI Research
30 June 2016 | By Victoria White, Digital Content Producer
The urological cancers market will increase from $17.9 billion in 2015 to $35.9 billion by 2022, according to business intelligence provider GBI Research...
Topline results from Phase II study of SHP607 in extremely premature infants
30 June 2016 | By Victoria White, Digital Content Producer
While the study did not meet its primary endpoint of reducing severity of ROP, it did produce encouraging secondary endpoints related to lung and brain...
Mundipharma obtains global ex-US rights to Zubsolv
30 June 2016 | By Victoria White, Digital Content Producer
Orexo’s Zubsolv (buprenorphine and naloxone sublingual tablet) is a potential new treatment option for patients with opioid dependence...
EFPIA releases statement on Brexit
30 June 2016 | By Victoria White, Digital Content Producer
In the statement, EFPIA underscores the importance of ensuring that the patient is at the centre of all subsequent decisions...
First patient enrolled in IPF biomarker study of Ofev
30 June 2016 | By Victoria White, Digital Content Producer
INMARK is a study investigating the effect of Ofev (nintedanib) on changes in specific blood biomarkers in patients with idiopathic pulmonary fibrosis...
Pneumococcal vaccine PnuBioVax safe and immunogenic in Phase I study
30 June 2016 | By Victoria White, Digital Content Producer
ImmBio has reported positive results from the First-in-Human study of its novel vaccine, PnuBioVax, against the bacterial pathogen Streptococcus pneumoniae...
MenABCWY set to revolutionise the meningococcal vaccine market
29 June 2016 | By Victoria White, Digital Content Producer
GlobalData says MenABCWY has the potential to significantly change the approach used to prevent meningococcal disease...
Regorafenib increases overall survival in hepatocellular carcinoma study
29 June 2016 | By Victoria White, Digital Content Producer
Results from the Phase III RESORCE trial investigating Bayer’s regorafenib in patients with unresectable hepatocellular carcinoma have been announced...
FDA approves Epclusa for treatment of chronic HCV
29 June 2016 | By Victoria White, Digital Content Producer
Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection...
Psoriasis survey reveals discrimination and low treatment expectations
29 June 2016 | By Victoria White, Digital Content Producer
Findings from the largest global survey to date of people with psoriasis reveal 84% of people with moderate-to-severe psoriasis suffer discrimination...
Controversy, media coverage and statin use in the UK
28 June 2016 | By Victoria White, Digital Content Producer
A study has found that controversy over the risks and benefits of statins was followed by an increase in people stopping their statin treatment...
SPIRE-HR and SPIRE-FH trials of bococizumab meet primary endpoints
28 June 2016 | By Victoria White, Digital Content Producer
Two Phase III trials of Pfizer’s bococizumab, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint...
